GENSCRIPT BIOTECH CORPORATION Funds and ETFs Genscript Biotech Corporation
Equities
1548
KYG3825B1059
Biotechnology & Medical Research
|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 11.76 HKD | +6.72% |
|
+12.64% | -40.79% |
ETFs positioned on Genscript Biotech Corporation
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 1.61% | 4 M€ | -27.92% | ||
| 1.43% | 2 M€ | -14.86% | - | |
| 0.56% | 3 M€ | +0.62% | - | |
| 0.49% | 2 M€ | -.--% | ||
| 0.47% | 2 M€ | -14.14% | ||
| 0.41% | 4 M€ | -11.56% | ||
| 0.18% | 7 M€ | -.--% | - | |
| 0.08% | 35 M€ | -5.85% | - | |
| 0.04% | 441 M€ | +4.60% | - | |
| 0.04% | 2,808 M€ | +6.68% | - | |
| 0.04% | 149 M€ | +2.17% | - | |
| 0.04% | 117 M€ | +1.54% | - | |
| 0.04% | 4 M€ | -4.41% | - | |
| 0.03% | 11 M€ | +2.69% | ||
| 0.01% | 31 M€ | +4.15% | - | |
| 0.00% | 7 M€ | +2.68% | - | |
| 0.00% | 389 M€ | +6.76% | - | |
| 0.00% | 34 M€ | +2.43% | - | |
| 0.00% | 147 M€ | +4.88% | - | |
| 0.00% | 34 M€ | +6.71% | - | |
| 0.00% | 39 M€ | +3.67% | - | |
| 0.00% | 302 M€ | +4.32% | - | |
| 0.00% | 17 M€ | +1.44% | - | |
| 0.00% | 108 M€ | +2.34% | - | |
| 0.00% | 15 M€ | +11.24% | ||
| 0.00% | 52 M€ | -0.13% | - | |
| 0.00% | 8 M€ | -0.60% | - |
Genscript Biotech Corporation is a Hong Kong-based investment holding company principally engaged in life science research and related businesses. The Company operates through four segments. Life Sciences Research Services segment includes gene and peptide synthesis, deoxyribonucleic acid (DNA) and primer synthesis, DNA sequencing, customized antibody production, protein expression and the production of stable cell lines. Preclinical Drug Development Services segment includes protein and antibody engineering, the study of in vitro drug and the study of in vivo drug. Life Sciences Research Catalog Products segment provides antibodies, recombinant proteins, equipment for protein isolation and analysis, molecular biology reagents, peptide, biochemicals and stable cell lines. Industrial Synthetic Biology Products segment is engaged in the development and production of industrial enzymes.
Calendar
2024-08-27
- Q2 2024 Earnings Release (Projected)
Trading Rating
Investor Rating
ESG Refinitiv
B
Sell
Buy
Mean consensus
BUY
Number of Analysts
13
Last Close Price
1.503
USD
Average target price
3.688
USD
Spread / Average Target
+145.47%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -40.79% | 2.99B | |
| +1.77% | 42.75B | |
| +47.70% | 41.61B | |
| +12.24% | 41.34B | |
| -8.83% | 26.59B | |
| +7.44% | 25.49B | |
| -23.01% | 18.12B | |
| +30.56% | 12.24B | |
| -1.82% | 11.76B | |
| +8.35% | 11B |
- Stock Market
- Equities
- 1548 Stock
- Funds and ETFs Genscript Biotech Corporation
